SCHEMBL4449623

SCHEMBL4449623

O=C(O)CCCCCCC/C=C/CO

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.67
PPARD Q03181 5/20 0.67
PPARA Q07869 5/20 0.67
F7 P08709 5/20 0.67
F3 P13726 5/20 0.67
MAPT P10636 4/20 0.67
HSD17B10 Q99714 4/20 0.67
TERT O14746 3/20 0.67
PTPN1 P18031 3/20 0.67
BLM P54132 3/20 0.67
FABP4 P15090 3/20 0.67
LMNA P02545 3/20 0.67
ALOX15 P16050 3/20 0.67
CYP19A1 P11511 3/20 0.67
PTGS1 P23219 3/20 0.67
TDP1 Q9NUW8 3/20 0.67
RECQL P46063 2/20 0.67
DUSP3 P51452 2/20 0.67
NR4A2 P43354 2/20 0.67
KMT2A Q03164 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4449624 1.00 PPARG (0.67) PPARGPPARDPPARAF7F3
SCHEMBL5379264 1.00 PPARG (0.67) PPARGPPARDPPARAF7F3
SCHEMBL5379268 1.00 PPARG (0.67) PPARGPPARDPPARAF7F3
SCHEMBL28304955 1.00 PPARG (0.67) PPARGPPARDPPARAF7F3
SCHEMBL16308004 1.00 PPARG (0.67) PPARGPPARDPPARAF7F3
SCHEMBL20197662 1.00 PPARG (0.67) PPARGPPARDPPARAF7F3
SCHEMBL16523047 1.00 PPARG (0.67) PPARGPPARDPPARAF7F3
SCHEMBL15320686 1.00 PPARG (0.67) PPARGPPARDPPARAF7F3
SCHEMBL8984377 0.98 PPARG (0.63) PPARGPPARDPPARAF7F3
SCHEMBL8327969 0.98 PPARG (0.63) PPARGPPARDPPARAF7F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118459485-A Amino-substituted heterocycles for the treatment of cancers with EGFR mutations 纽威伦特公司 2024-08-09 CN disclosed
CN-117500803-A Amino-substituted heterocycles for the treatment of cancers with EGFR mutations 纽威伦特公司 2024-02-02 CN disclosed
CN-116546986-A ALK-5 inhibitors and uses thereof 住友制药肿瘤公司 2023-08-04 CN disclosed
US-10906861-B2 Methods of making organic compounds by metathesis WILMAR TRADING PTE LTD (SG) 2021-02-02 US disclosed
US-10087137-B2 Cross metathesis approach to C11-C13 fatty-chain amino esters from oleic acid derivatives THE UNIVERSITY OF TOLEDO (US) 2018-10-02 US disclosed
EP-3281931-A1 METHODS OF MAKING ORGANIC COMPOUNDS BY METATHESIS Elevance Renewable Sciences, Inc. (US) 2018-02-14 EP disclosed
US-20170204051-A1 Cross Metathesis Approach to C11-C13 Fatty-Chain Amino Esters From Oleic Acid Derivatives THE UNIVERSITY OF TOLEDO (US) 2017-07-20 US disclosed
EP-3008078-A1 CATALYSTS FOR EFFICIENT Z-SELECTIVE METATHESIS Trustees of Boston College (US) 2016-04-20 EP disclosed
WO-2015200200-A1 CROSS METATHESIS APPROACH TO C11-C13 FATTY-CHAIN AMINO ESTERS FORM OLEIC ACID DERIVATIVES THE UNIVERSITY OF TOLEDO (US) 2015-12-30 WO disclosed
US-20150307438-A1 Methods of Making Organic Compounds by Metathesis ELEVANCE RENEWABLE SCIENCES, INC. (US) 2015-10-29 US disclosed
US-9120742-B2 Methods of making organic compounds by metathesis ELEVANCE RENEWABLE SCIENCES, INC. (US) 2015-09-01 US disclosed
WO-2014201300-A1 CATALYSTS FOR EFFICIENT Z-SELECTIVE METATHESIS TRUSTEES OF BOSTON COLLEGE (US) 2014-12-18 WO disclosed
US-20090264672-A1 METHODS OF MAKING ORGANIC COMPOUNDS BY METATHESIS ELEVANCE RENEWABLE SCIENCES, INC. (US) 2009-10-22 US disclosed
US-7247697-B2 Coating compositions for use in golf balls ACUSHNET COMPANY (US) 2007-07-24 US disclosed
US-20060089419-A1 Coating compositions for use in golf balls JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264672-A1 METHODS OF MAKING ORGANIC COMPOUNDS BY METATHESIS COASY, FASN, HAO2 PPARG 1388/4885PPARD 352/4885PPARA 879/4885
US-10906861-B2 Methods of making organic compounds by metathesis COASY, FASN, HAO2 PPARG 1388/4885PPARD 352/4885PPARA 879/4885
US-20150307438-A1 Methods of Making Organic Compounds by Metathesis COASY, FASN, HAO2 PPARG 1388/4885PPARD 352/4885PPARA 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.